

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

APPOINTMENT OF EXECUTIVE DIRECTOR AND AUTHORISED REPRESENTATIVES

The Board is pleased to announce the appointment of Mr. Gao Yuan Xing as an executive director of the Company and as one of the authorised representatives of the Company as required under Rule 3.05 of the Listing Rules and the authorised representative of the Company for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance with effect from 4 January 2016.

This announcement is made by Innovative Pharmaceutical Biotech Limited (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

APPOINTMENT OF EXECUTIVE DIRECTOR AND AUTHORISED REPRESENTATIVES

The board of directors (the “**Board**”) of the Company is pleased to announce the appointment of Mr. Gao Yuan Xing (“**Mr. Gao**”) as an executive director and as one of the authorised representatives of the Company as required under Rule 3.05 of the Listing Rules and the authorised representative of the Company for accepting service of process and notices on behalf of the Company in Hong Kong as required under Part 16 of the Companies Ordinance (Chapter 622 of the laws of Hong Kong) (the “**Companies Ordinance**”) with effect from 4 January 2016.

The biological details of Mr. Gao are set out as follows:

Mr. Gao Yuan Xing, aged 61, from 15 March 2011 to 4 January 2016, Mr. Gao was the chairman and executive director of North Mining Shares Company Limited, a company listed on the Main Board of The Stock Exchange in Hong Kong (the “**Stock Exchange**”) (Stock Code: 433). Mr. Gao has completed the course of Senior Manager Class in Shanghai Institute of Foreign Trade. He has abundant experience in energy management, and worked in the foreign affairs office of Shanghai Municipal Government for many years. Mr. Gao had also been senior management in the number of international, mainland investment and commercial companies.

Mr. Gao has entered into a service contract with the Company for a term of three years, and is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the bye-laws of the Company. Mr. Gao will receive emolument of HK\$910,200 per annum which is determined by the Board with reference to his experience, duties and responsibilities in the Company as well as the current market rate.

As at the date of this announcement, Mr. Gao does not have any interest (within the meaning of Part XV of the Securities Futures Ordinance) in the securities of the Company.

Save as disclosed in this announcement, Mr. Gao held no other directorship in any listed public company in the last three years preceding the date of his appointment. Further, Mr. Gao does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

Mr. Gao has not been involved in any of the events under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to his appointment as an executive director that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express its warmest welcome to Mr. Gao for joining the Board.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Jiang Nian
Chairman

Hong Kong, 4 January 2016

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive director), Mr. Gao Yuan Xing (executive director), Mr. Tang Rong (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).

* *For identification purpose only*